Get the Stockscreener App
1.60
2.44%
-0.04
After Hours:
1.62
0.02
+1.25%
Medicinova Inc Stock (MNOV) Latest News
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MediciNova (NASDAQ:MNOV) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
MediciNova (NASDAQ:MNOV) Releases Earnings Results, Hits Estimates - MarketBeat
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Geode Capital Management LLC - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
US Penny Stocks To Watch In December 2024 - Simply Wall St
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Zacks sees 400% upside for MediciNova amid incoming damages from Sanofi/Novartis dispute - Kursiv Media
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement - Smartkarma
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):